Omicron variant (B. 1.1. 529): infectivity, vaccine breakthrough, and antibody resistance
The latest severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant Omicron
(B. 1.1. 529) has ushered panic responses around the world due to its contagious and …
(B. 1.1. 529) has ushered panic responses around the world due to its contagious and …
mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant
The Omicron variant of SARS-CoV-2 is causing a rapid increase in infections across the
globe. This new variant of concern carries an unusually high number of mutations in key …
globe. This new variant of concern carries an unusually high number of mutations in key …
[HTML][HTML] Antibody evasion properties of SARS-CoV-2 Omicron sublineages
The identification of the Omicron (B. 1.1. 529.1 or BA. 1) variant of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) in Botswana in November 2021 1 immediately …
syndrome coronavirus 2 (SARS-CoV-2) in Botswana in November 2021 1 immediately …
[PDF][PDF] Therapeutics and COVID-19: living guideline, 13 January 2023
World Health Organization - 2023 - apps.who.int
As of December 2022, there have been over 642 million confirmed cases of COVID-19 (10).
The pandemic has thus far claimed approximately 6.62 million lives (10). Vaccination is …
The pandemic has thus far claimed approximately 6.62 million lives (10). Vaccination is …
Characterization of the enhanced infectivity and antibody evasion of Omicron BA. 2.75
Summary Recently emerged SARS-CoV-2 Omicron subvariant, BA. 2.75, displayed a growth
advantage over circulating BA. 2.38, BA. 2.76, and BA. 5 in India. However, the underlying …
advantage over circulating BA. 2.38, BA. 2.76, and BA. 5 in India. However, the underlying …
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans
YM Loo, PM McTamney, RH Arends… - Science translational …, 2022 - science.org
Despite the success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
vaccines, there remains a need for more prevention and treatment options for individuals …
vaccines, there remains a need for more prevention and treatment options for individuals …
The humoral response and antibodies against SARS-CoV-2 infection
Two and a half years into the COVID-19 pandemic, we have gained many insights into the
human antibody response to the causative SARS-CoV-2 virus. In this Review, we …
human antibody response to the causative SARS-CoV-2 virus. In this Review, we …
[HTML][HTML] Neutralizing monoclonal antibodies for treatment of COVID-19
PC Taylor, AC Adams, MM Hufford… - Nature Reviews …, 2021 - nature.com
Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …
The development of COVID-19 treatment
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …
Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies
FA Lempp, LB Soriaga, M Montiel-Ruiz, F Benigni… - Nature, 2021 - nature.com
Abstract SARS-CoV-2 infection—which involves both cell attachment and membrane fusion—
relies on the angiotensin-converting enzyme 2 (ACE2) receptor, which is paradoxically …
relies on the angiotensin-converting enzyme 2 (ACE2) receptor, which is paradoxically …